Previous 10 | Next 10 |
home / stock / mrk / mrk articles
Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and...
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its ...
On CNBC's “Halftime Report Final Trades,” Liz Young of SoFi named The Energy Select Sector SPDR Fund (NYSE:XLE) as her final trade...
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage tri...
In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry obse...
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis f...
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursda...
Merck & Co., Inc. (NYSE:MRK) is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum of $1.3 billion. This acquisition i...
News, Short Squeeze, Breakout and More Instantly...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation (“Orion”) today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for o...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 30. During the call, company executives will provide an overview of Merck’...
If approved by the European Commission, WINREVAIR will be the first activin signaling inhibitor therapy for PAH in Europe, offering a new treatment option for certain adults with this rare, progressive disease Milestone highlights Merck’s focus on global filings to expand access to...